GENE ONLINE|News &
Opinion
Blog

Sanofi
Sanofi and Regeneron’s Dupixent Snags its Tenth Approval From the FDA
2022-09-29
AstraZeneca, Sanofi’s RSV Antibody Recommended For Approval In EU
2022-09-19
Sanofi’s Rare Disease Drug Granted First-Ever FDA Approval for the Condition
2022-09-01
Sanofi’s Treatment for Hemophilia A has a Concrete FDA Decision Date
2022-08-30
Sanofi Abandons SERD Candidate After Second Breast Cancer Clinical Trial Blow
2022-08-18
Sanofi Invests in Innovent to Gain Stronger Foothold in China
2022-08-05
Sanofi and Regeneron Post Positive Results from Child Throat Disease Trial
2022-07-15
Sanofi’s siRNA Therapy Reduces Bleeds in Hemophilia, Meets Primary Endpoint
2022-07-12
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
FDA Panel Suggests Redesigning Vaccines to Target Omicron Variants, Pfizer & Sanofi Share Booster Updates
2022-06-29
Sanofi’s New Pompe Disease Treatment Wins Approval in Europe
2022-06-29
FDA OKs First Biologic for Children Under 5 With Moderate-to-Severe Atopic Dermatitis
2022-06-08
Sanofi and Sobi Receive Breakthrough Therapy Designation for Hemophilia A Drug
2022-06-02
Sanofi’s Trial to Make Cialis Available Over-the-Counter Meets FDA Hold
2022-05-31
Emerging NY Biotech Furthers Sanofi’s CNS Therapeutics
2022-04-22
1 2 3
LATEST
A New Sequencer on the Horizon – Illumina Genomics Forum Days Two and Three Highlights
2022-09-30
Novo Nordisk Places $700 Million Bet on Ventus’ NLRP3 Inhibitor Program
2022-09-30
Amylyx’s ALS Drug Nabs FDA Nod After Rare Regulatory Reversal
2022-09-29
Illumina Reveals NovaSeq™ X Series at the Illumina Genomics Forum
2022-09-29
Illumina Genomics Forum Kicks Off With A Conversation With President Barack Obama
2022-09-29
First Patient in New Zealand Dosed with Illuccix® – Telix's Prostate Cancer Imaging Agent
2022-09-29
Samsung Biologics introduces new development platforms S-DUAL™ and DEVELOPICK™ at BPI Boston 2022
2022-09-29
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!